Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2004 | 12-2003 | 12-2002 | 12-2001 | 12-2000 | |
| Sales | 27,277,000 | 24,930,000 | 20,877,000 | 18,762,000 | 19,070,000 |
| Cost of Goods | 6,700,000 | 6,457,000 | 4,994,000 | 4,744,000 | 4,694,000 |
| Gross Profit | 20,577,000 | 18,473,000 | 15,883,000 | 14,018,000 | 14,376,000 |
| Operating Expenses | 14,460,000 | 12,838,000 | 10,791,000 | 9,693,000 | 10,045,000 |
| Operating Income | 6,117,000 | 5,635,000 | 5,092,000 | 4,325,000 | 4,331,000 |
| Interest Expense | 261,000 | 243,000 | 0 | 0 | 0 |
| Other Income | 554,000 | 342,000 | 606,000 | 367,000 | 718,000 |
| Pre-tax Income | 6,410,000 | 5,734,000 | 5,698,000 | 4,692,000 | 5,049,000 |
| Income Tax | 1,045,000 | 947,000 | 959,000 | 844,000 | 857,000 |
| Net Income Continuous | 5,365,000 | 4,787,000 | 4,739,000 | 3,848,000 | 4,181,000 |
| Net Income Discontinuous | 15,000 | N/A | N/A | N/A | 0 |
| Minority Interests | 15,000 | 44,000 | 14,000 | 12,000 | N/A |
| Net Income | $5,365,000 | $4,743,000 | $4,725,000 | $3,836,000 | $4,181,000 |
| EPS Basic Total Ops | 2.28 | 1.99 | 1.88 | 1.49 | 1.45 |
| EPS Basic Continuous Ops | 2.27 | 2.01 | 1.88 | 1.50 | 1.45 |
| EPS Basic Discontinuous Ops | 0.01 | N/A | N/A | N/A | N/A |
| EPS Diluted Total Ops | 2.27 | 1.97 | 1.84 | 1.49 | N/A |
| EPS Diluted Continuous Ops | 2.26 | 1.98 | 1.84 | 1.49 | N/A |
| EPS Diluted Discontinuous Ops | 0.01 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $7,465,000 | $7,021,000 | $6,428,000 | $5,381,000 | $4,908,000 |